智通财经网·2025-10-14 09:17Core Viewpoint - Bank of America Securities has released a report indicating that JD Health's performance in the first half of 2025 significantly exceeded expectations, with continued strong performance anticipated in the second half of the year [1] Group 1: Revenue and Profit Forecasts - The revenue growth forecast for JD Health in 2025 has been revised upward from 20% to 22% [1] - The adjusted operating profit growth forecast has been increased from 32% to 40% [1] - The adjusted net profit forecast for JD Health from 2025 to 2027 has been raised by 3% based on a more optimistic growth outlook [1] Group 2: Target Price and Ratings - The discounted cash flow target price for JD Health has been raised from HKD 68 to HKD 71 [1] - Bank of America Securities has reiterated its "Buy" rating for JD Health [1] Group 3: Quarterly Expectations - For the third quarter, Bank of America Securities has revised its forecasts for JD Health, expecting the company to maintain rapid revenue growth momentum from the first half [1] - The fourth quarter forecast remains conservative, pending more visibility after the Double Eleven shopping festival [1] - The expectation is that JD Health's gross margin will achieve year-on-year expansion in the second half of the year [1]